Pieris Pharmaceuticals, Inc. (OTCQB: PIRS), a biotechnology company advancing its proprietary Anticalin® biotherapeutic technologies announced today that President and CEO, Stephen Yoder, will present preclinical data on a new immuno-oncology program—an Anticalin-based CD137-HER2 bispecific—at the UBS Global Healthcare Conference at 4:30 pm EDT.